Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)

Jefferies analyst Matthew Taylor maintained a Buy rating on Integra Lifesciences (IART – Research Report) today and set a price target of $50.00. The company’s shares closed last Friday at $28.68.

According to TipRanks, Taylor is a 5-star analyst with an average return of 10.0% and a 61.00% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Dexcom, Edwards Lifesciences, and Integra Lifesciences.

Integra Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $43.50.

IART market cap is currently $2.24B and has a P/E ratio of 34.01.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Integra Lifesciences (IART) Company Description:

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.